Medpace二季度业绩超预期并上调全年指引，但同一催化已在系统内多次处理

Tesla slumps 10% after earnings miss on softer automotive margins
Introduction & Market Context
Medpace Holdings (NASDAQ:MEDP) presented its second quarter 2026 financial results on July 23, 2026, showcasing robust growth across key operating metrics and raising its full-year guidance. The clinical research organization reported revenue of $707.3 million, up 17.2% year-over-year, while net new business awards surged 28.2% to $795.7 million, producing a book-to-bill ratio of 1.13x.
The strong performance sent shares up 17.8% to $622 in after-hours trading, approaching the company’s 52-week high of $677.9. The results beat analyst expectations, with diluted earnings per share of $4.25 exceeding forecasts by 6.78% and revenue topping consensus by 2.41%.
Quarterly Performance Highlights
The company’s second quarter results demonstrated accelerating momentum across multiple dimensions. As shown in the following table of key operating metrics, Medpace delivered broad-based growth while expanding its backlog and improving conversion rates.
Revenue for the quarter reached $707.3 million, representing 17.2% growth from $603.3 million in the prior-year period. Year-to-date revenue totaled $1,413.9 million, up 21.7% from $1,161.9 million in the first half of 2025. The acceleration in bookings was particularly notable, with net new business awards climbing to $795.7 million from $620.5 million a year earlier.
The company’s backlog position remained strong at $3,014.2 million, up 4.9% year-over-year, while the backlog conversion rate increased to 24.1% from 21.2% in the prior-year quarter. This elevated conversion rate suggests improving execution and a shift toward faster-burning studies. Headcount grew 7.3% to 6,479 employees, supporting the company’s revenue expansion.
The following charts illustrate the quarterly progression of key operational metrics, showing sustained improvement in bookings momentum and backlog conversion rates over the past two years.
The book-to-bill ratio of 1.13x in the second quarter marked a significant improvement from 1.03x a year earlier, indicating that new business awards are outpacing revenue recognition. Net new business awards have shown particular strength in recent quarters, with the second quarter representing the second-highest quarterly bookings in the company’s history.
Detailed Financial Analysis
Medpace’s profitability metrics demonstrated strong performance in the second quarter, with earnings growth outpacing revenue expansion. The company’s key financial highlights reveal both top-line momentum and bottom-line efficiency.
EBITDA reached $153.4 million in the second quarter, up 17.6% from $130.5 million in the prior year, while maintaining a stable margin of 21.7% compared to 21.6% a year earlier. Net income grew 34.5% to $121.4 million, significantly outpacing revenue growth due to a lower effective tax rate and higher interest income on the company’s cash position.
Diluted earnings per share of $4.25 represented 37.1% growth from $3.10 in the second quarter of 2025. The company noted that on a constant currency basis, revenue increased 17.2% and EBITDA grew 17.8% in the quarter.
The following chart shows the quarterly progression of revenue and EBITDA over the past two years, illustrating consistent growth with relatively stable margins.
Operating expenses totaled $560.5 million, or 79.2% of revenue, compared to $477.0 million, or 79.1% of revenue, in the prior-year quarter. Direct service costs excluding depreciation and amortization represented 28.6% of revenue, while reimbursed out-of-pocket expenses accounted for 42.9% of revenue. Income from operations increased to $146.8 million from $126.3 million a year earlier.
The company’s long-term financial trajectory demonstrates sustained growth across both revenue and profitability metrics, as illustrated in the annual trends below.
From 2021 through 2025, Medpace achieved a revenue compound annual growth rate of approximately 20%, with EBITDA growing at an even faster 23% CAGR. The company’s 2026 guidance suggests continued double-digit growth, albeit at a moderating pace as the business scales.
Net income and earnings per share have grown at even faster rates, with net income CAGR of 22-23% and EPS CAGR approaching 30% over the five-year period through 2025. This outperformance reflects both operational leverage and effective capital allocation through share repurchases.
Strategic Positioning
The company’s revenue composition showed notable shifts in the second quarter, with implications for future growth drivers. The therapeutic area mix revealed a significant change from the prior year, with metabolism-focused studies now representing the largest share of revenue.
Metabolism studies accounted for 32% of revenue in the last twelve months ending Q2 2026, up from 25% a year earlier, while oncology represented 29%, down from 31%. During the earnings call, CEO August Troendle noted that oncology has recently regained momentum in bookings, representing over half of new awards and award notifications, while cardiometabolic programs "dropped off quite a bit in terms of new award notifications."
Customer concentration also increased notably, with the top five customers accounting for 31% of revenue over the last twelve months, up from 20% a year earlier. Small biopharma companies continued to represent the bulk of revenue at 84%, up from 80%, while large pharma remained steady at 5% of revenue.
Cash Generation and Capital Allocation
Medpace demonstrated strong cash flow generation in the second quarter, though free cash flow conversion moderated from elevated prior-year levels. The company’s cash position and capital allocation activities are detailed in the following metrics.
Operating cash flow reached $162.0 million in the second quarter, compared to $148.5 million a year earlier. After capital expenditures of $23.9 million, free cash flow totaled $138.1 million, representing 90.0% conversion of EBITDA. This compared to 109.2% conversion in the prior-year quarter, with the moderation reflecting higher capital spending and working capital timing.
The company’s cash balance stood at $502.7 million at quarter-end, down from $652.7 million at the end of the first quarter, primarily due to share repurchases. Medpace repurchased $294.7 million of shares during the second quarter, bringing year-to-date repurchases to $294.7 million compared to $908.4 million in the first half of 2025.
Net days sales outstanding remained negative at ($59.6), indicating that customer advances continue to exceed accounts receivable, a favorable working capital position typical of the contract research industry.
Forward-Looking Statements
Medpace raised its full-year 2026 guidance across all key metrics, reflecting confidence in sustained momentum through the second half of the year. The updated guidance represents a meaningful increase from the company’s previous outlook provided in April.
The company now expects full-year revenue of $2,805 million to $2,885 million, representing growth of 10.9% to 14.0% from 2025 levels. This compares to prior guidance of $2,755 million to $2,855 million. EBITDA guidance increased to a range of $618 million to $642 million, up from $605 million to $635 million previously.
Net income is projected at $494 million to $514 million, with diluted earnings per share expected to reach $17.25 to $17.95, representing growth of 12.9% to 17.5%. The guidance assumes a tax rate of 19.0% to 19.5% for the full year and does not reflect the potential impact of additional share repurchases.
Management indicated that it expects gross bookings to ramp in the second half of the year, with net bookings likely to improve assuming cancellations remain at reasonable levels. The company also projected that direct service costs would run at 41% to 42% of revenue in the third and fourth quarters, benefiting from a decline in reimbursable costs as a percentage of revenue.
Employee growth is expected to remain in the high single digits for 2026 and 2027, with hiring concentrated in the United States and Asia Pacific, including India. Management anticipates margin expansion in the second half of the year as revenue growth outpaces headcount growth.
During the earnings call, executives noted that the business environment strengthened in the second quarter, with cancellations "well-behaved" and RFP activity improving both sequentially and year-over-year. The quality of opportunities also improved as more customers came to market with fresh capital, reflecting a healthier biotech funding environment.
However, management acknowledged certain risks, including the unpredictability of cancellations, increased customer concentration, and backlog conversion rates running above historical norms. The therapeutic mix shift, with cardiometabolic demand weakening after a strong period, also represents a notable change in the business composition.
The company’s presentation included standard forward-looking statement disclaimers, noting various risks including potential loss of contracts, non-payment by customers, failure to convert backlog to revenue, cybersecurity threats, and competitive pressures that could materially affect financial results.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.